Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7-59 months. A matched case-control study

Vaccine

Volumn 29, Issue 48, 2011, Pages 9020-9025

  Domínguez, Angela ^a,b   Ciruela, Pilar ^c   García García, Juan José ^d   Moraga, Fernando ^e   Sevilla, Mariona F de ^d   Selva, Laura ^d   Coll, Francis ^e   Muñoz Almagro, Carmen ^d   Planes, Ana María ^e   Codina, Gemma ^e   Jordán, Iolanda ^d   Esteva, Cristina ^d   Hernández, Sergi ^c   Soldevila, Núria ^b   Cardeñosa, Neus ^b   Batalla, Joan ^b,c   Salleras, Luis ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c AGÈNCIA DE SALUT PÚBLICA DE BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Case control study; Effectiveness; Pneumococcal conjugate vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; CASE CONTROL STUDY; CELLULITIS; CHILD; CHILD HEALTH; CONFOUNDING VARIABLE; CONTROLLED STUDY; EMPYEMA; FEMALE; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRESCHOOL CHILD; PRIMARY HEALTH CARE; PRIORITY JOURNAL; SEPSIS; SEROTYPE; THERAPY EFFECT; UNIVERSITY HOSPITAL; VACCINATION;

CASE-CONTROL STUDIES; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; LOGISTIC MODELS; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POPULATION SURVEILLANCE; SPAIN; VACCINES, CONJUGATE;

EID: 82455218942     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.034     Document Type: Article

References (38)

1. Fedson D.S., Musher D.M. Pneumococcal vaccine. Vaccines 1999, 553-607. WB Saunders, Philadelphia. 3rd ed. S.A. Plotkin, W.A. Orenstein (Eds.).
2. Salleras L., Domínguez A., Navarro J.á. Vacuna antineumocócica conjugada. Vacunaciones preventivas 2003, 399-420. Masson, Barcelona. 2nd ed. L. Salleras (Ed.).
3. Poland G. The burden of pneumococcal disease: the role of conjugate vaccines. Vaccine 1999, 17:1674-1679.
4. Butler J.C., Hofmann J., Cetron M.S., Elliott J.A., Facklam R.R., Breiman R.F. The continued emergence of drug-resistant Streptococcus pneumoniae in the US: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect Dis 1996, 174:986-993.
5. Black S., Shinefield H., Fireman B., Lewis E., Ray P. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000, 19:187-195.
6. CDC Advisory Committee on Immunization Practices Preventing pneumococcal disease among infants and children. Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2000, 49(RR-9):1-35.
7. Butler J.C., Breiman R.F., Lipman H.B., Hofmann J., Facklam R.R. Serotype distribution of streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine. J Infect Dis 1995, 171:885-889.
8. Salleras L., Fenoll A., Domínguez A., Navas E., Casal J. Cobertura de serotipos de la vacuna antineumocócica conjugada heptavalente, Cataluña, 1997-2002. Vacunas 2003, 4:73-79.
9. Bernaola E., Giménez F., Baca M., De Juan F., Diez J., Garcés M., et al. Vaccination schedule of the Spanish association of pediatrics: recommendations. An Pediatr (Barc) 2009, 70:72-82.
10. Borras E. Study of vaccination coverage in children under 3 years of age in Catalonia (Spain). Doctoral Thesis. University of Barcelona, Spain. Updated 2006, [accessed 2.05.2011]. http://www.tdx.cat/handle/10803/2845.
11. Calbo E., Díaz A., Cañadell E., Fábrega J., Uriz S., Xercavins M., et al. Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine. Clin Microbiol Infect 2006, 12:867-872.
12. Muñoz-Almagro C., Jordan I., Gene A., Latorre C., Garcia-Garcia J.J., Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008, 46:174-182.
13. Salleras L., Domínguez A., Ciruela P., Izquierdo C., Borras E. Impacto de la vacuna neumocócica conjugada heptavalente en una población con valores bajos-intermedios de vacunación. Enf Infecc Microbiol Clin 2009, 27:275-277.
14. Hicks L.A., Harrison L.H., Flannery B., Hadler J.L., Schaffner W., Craig A.S., et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007, 9:1346-1354.
15. Ciruela P., Hernández S., Izquierdo C. Epidemiology of invasive pneumococcal disease (2001-2008). Butlletí Epidemiològic de Catalunya 2010, XXX(2):31-37.
16. Salleras L., Domínguez A., Ciruela P., Izquierdo C., Navas E., Torner N., et al. Changes in serotypes causing invasive pneumococcal disease (2005-2007 vs 1997-1999) in children under 2 years of age in a population with intermediate coverage of the 7-valent pneumococcal conjugated vaccine. Clin Microbiol Infect 2009, 15:997-1001.
17. Salleras L. The emergence of non-vaccine serotypes in invasive pneumococcal disease: a probably multifactorial origin. Vacunas 2008, 9(Suppl. 1):3-11.
18. Obando I., Muñoz-Almagro C., Arroyo L.A., Tarrago D., Sanchez-Tatay D., Moreno-Perez D., et al. Pediatric parapneumonic empyema. Spain. Emerg Infect Dis 2008, 14:1390-1397.
19. Picazo J., Ruiz-Contreras J., Casado-Flores J., Giangaspro E., Del Castillo F., Hernández-Sampelayo T., et al. Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar. Clin Vaccine Immunol 2011, 18:89-94.
20. Whitney C.G., Pilishvili T., Farley M.M., Schaffner W., Craig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368:1495-1502.
21. Deceuninck G., De Wals P., Bouliannne N., De Serres G. Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada. Pediatr Infect Dis J 2010, 29:546-549.
22. Barricarte A., Castilla J., Gil-Setas A., Torroba L., Navarro-Alonso J.A., Irisarri F., et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study. Clin Infect Dis 2007, 44:1436-1441.
23. Mahon B.E., Hsu K., Karumuri S., Kaplan S.L., Mason E.O., Pelton S.I., et al. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine 2006, 24:2514-2520.
24. Ruckinger J., van der Linden M., Reinert R.R., von Kries R. Efficacy of 7-valent pneumococcal conjugate vaccination in Germany: an analysis using the indirect cohort method. Vaccine 2010, 28:5012-5016.
25. Muñoz-Almagro C., Gala S., Selva L., Jordan I., Tarragó D., Pallares R. DNA bacterial load in children and adolescents with pneumococcal pneumonia and empyema. Eur J Clin Microbiol Infect Dis 2011, 30:327-335.
26. Tarragó D., Fenoll A., Sanchez-Tatay D., Arroyo L.A., Muñoz-Almagro C., Esteva C., et al. Identification of pneumococcal serotypes from culture-negative clinical specimens by novel real-time PCR. Clin Microbiol Infect 2008, 14:828-834.
27. American Academy of Pediatrics 2009 Report of the committee on infectious diseases 2009, American Academy of Pediatrics, Elk Grove Village. 28th ed.
28. Office of Population Censuses Surveys Classification of occupations 1980, HMSO, London.
29. Schlesselman J.J. Case-control studies: design, conduct analysis 1982, Oxford University Press, New York, pp. 144-70.
30. Hausdorff W.P. Invasive pneumococcal disease in children: geographic and temporal variations in incidence and serotype distribution. Eur J Pediatr 2002, 161(Suppl. 2):135-139.
31. Grijalva C.G., Nuorti J.P., Zhu Y., Griffin M.R. Increasing incidence of empyema complicating childhood community-acquired pneumonia in the United States. Clin Infect Dis 2010, 50:805-813.
32. Koshy E., Murray J., Bottle A., Sharland M., Saxena S. Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997-2008. Thorax 2010, 65:770-774.
33. Pelton S.I., Weycker D., Klein J.O., Srutton D., Ciuryla V., Oster G. 7-valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series. Vaccine 2010, 28:1575-1582.
34. Esteva C., Selva L., de Sevilla M.F., García-García J.J., Pallarés R., Muñoz-Almagro C. Streptococcus pneumoniae serotype 1 causing invasive disease among children in Barcelona over a 20-year period (1989-2008). Clin Microbiol Infect 2011, 17:1441-1444.
35. Spijkerman J., van Gils E.J., Veenhoven R.H., Hak E., Yzerman E.P., van der Ende A., et al. Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the Netherlands. Emerg Infect Dis 2011, 17:584-591.
36. Gonçalves G. Herd immunity: recent uses in vaccine assessment. Expert Rev Vaccines 2008, 7:1493-1506.
37. Centers for Disease Control Prevention Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease. United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005, 54:893-897.
38. Azzari C., Moriondo M., Indolfi G., Massai C., Becciolini L., de Martino M., et al. Molecular detection methods and serotyping performed directly on clinical samples improve diagnostic sensitivity and reveal increased incidence of invasive disease by Streptococcus pneumoniae in Italian children. Med Microbiol 2008, 57:1205-1212.